Data mining combined with experiments to validate CEP55 as a prognostic biomarker in colorectal cancer

Kang, Lin; Zhu, Xiaojian; Luo, Chen; Bu, Fanqin; Zhu, Jinfeng; Zhu, Zhengming

doi:10.1002/iid3.375

Cited by 9 publications

(6 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To promote the clinical transformation of platelet-associated subtypes, we developed a four-gene signature that predict pancreatic cancer. CEP55 (Centrosome protein 55) was considered essential for cell cycle processes, and there were increasing evidences that up-regulation of CEP55 was involved in the development and progression of various malignancies, including liver cancer [ 16 ], bladder cancer [ 17 ], anaplastic thyroid cancer [ 18 ], non-small-cell lung cancer [ 19 , 20 ] and colorectal cancer [ 21 ]. And overexpression of CEP55 was associated with genomic instability [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma

Zhao

et al. 2023

BMC Med Genomics

View full text Add to dashboard Cite

Background Pancreatic adenocarcinoma (PDAC) is a malignant tumor with high heterogeneity and poor prognosis. In this study, we sought to identify the value of platelet-related genes in prognosis and heterogeneity of PDAC through multiple transcriptomic methods. Methods Based on datasets from Gene Expression Omnibus and The Cancer Genome Atlas (TCGA), platelet-related genes were screened out, and the TCGA cohort (n = 171) was identified into two subtypes by unsupervised clustering. The platelet-related risk score model (PLRScore) was constructed by univariate Cox and LASSO regression, and the predictive ability was evaluated by Kaplan-Meier test and time-dependent receiver operating characteristic (ROC) curves. The results were validated in two other external validation sets, ICGC-CA (n = 140) and GSE62452 (n = 66). Furthermore, predictive nomogram containing clinical characteristics and PLRScore was established. In addition, we determined the possible correlation between PLRScore and immune infiltration and response of immunotherapy. Finally, we analyzed the heterogeneity of our signature in various types of cells using single-cell analysis. Results Platelet-related subtypes that have significant difference of overall survival and immune states (p < 0.05) were identified. PLRScore model based on four-gene signature (CEP55, LAMA3, CA12, SCN8A) was constructed to predict patient prognosis. The AUCs of training cohort were 0.697, 0.687 and 0.675 for 1-, 3-and 5-year, respectively. Further evaluation of the validation cohorts yielded similar results. In addition, PLRScore was associated with immune cell infiltration and immune checkpoint expression, and had promising ability to predict response to immunotherapy of PDAC. Conclusions In this study, the platelet-related subtypes were identified and the four-gene signature was constructed and validated. It may provide new insights into the therapeutic decision-making and molecular targets of PDAC.

show abstract

Section: Discussionmentioning

confidence: 99%

Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma

Zhao

et al. 2023

BMC Med Genomics

View full text Add to dashboard Cite

show abstract

“…CEP55, a centrosomal protein, regulates cytokinesis and is upregulated in tumorigenesis [ 43 ]. A recent study has shown that CEP55 expression is increased in the tissue of colorectal cancer (CRC) and promotes the proliferation of CRC cells through interactions with p53/p21 signaling proteins [ 44 ]. CEP55 deletion can prime premature CDK1/cyclin B activation and mitotic cell death, thus sensitizing breast cancer cells to antimitotic drugs [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)

Liu

2022

Cancers

View full text Add to dashboard Cite

Cyclin-dependent kinase 1 (CDK1) is essential for cell division by regulating the G2/M phase and mitosis. CDK1 overexpression can also promote the development and progression of a variety of cancers. However, the significance of CDK1 in the formation, progression, and prognosis of human pan-cancer remains unclear. In the present study, we used The Cancer Genome Atlas database, Clinical Proteomic Tumor Analysis Consortium, Human Protein Atlas, Genotype-Tissue Expression, and other well-established databases to comprehensively examine CDK1 genetic alterations and gene/protein expression in various cancers and their relationships with the prognosis, immune reactivities, and clinical outcomes for 33 tumor types. Gene set enrichment analysis was also conducted to examine the potential mechanisms of CDK1 in tumorigenesis. The data showed that CDK1 mutation was frequently present in multiple tumors. CDK1 expression was significantly increased in various types of tumors as compared with normal tissues and was associated with poor overall and disease-free survival. In addition, CDK1 expression was significantly correlated with oncogenic genes, proteins, cellular components, myeloid-derived suppressor cell infiltration, ESTMATEScore, and signaling pathways associated with tumor development and progression and tumor microenvironments. These data indicate that CDK1 could serve as a promising biomarker for predicting tumor prognosis and a potential target for cancer treatment.

show abstract

“…Metastasis and the relapse rate are vital in cancer diagnosis, and any biomarker that could provide an index for these factors would prove highly beneficial. Of particular interest might be stromal cell-derived factor 1 (CXCL12), cyclin-dependent kinases regulatory subunit 2 (CKS2), metalloproteinase inhibitor 1 (TIMP1), centrosomal protein of 55 (CEP55), and guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 (GNG2), for which overexpression has been linked to higher relapse rates [123][124][125][126][127][128][129][130]. There are several differentially expressed genes in CRC that are believed to be associated with the epigenetics of DNA and miRNA.…”

Section: Differential Gene and Protein Expression In Crcmentioning

confidence: 99%

Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection

Kamel

Eltarhoni

Nisar

et al. 2022

Cancers

View full text Add to dashboard Cite

Globally, colorectal cancer (CRC) is the third most common cancer, with 1.4 million new cases and over 700,000 deaths per annum. Despite being one of the most common cancers, few molecular approaches to detect CRC exist. Carcinoembryonic antigen (CEA) is a known serum biomarker that is used in CRC for monitoring disease recurrence or response to treatment. However, it can also be raised in multiple benign conditions, thus having no value in early detection or screening for CRC. Molecular biomarkers play an ever-increasing role in the diagnosis, prognosis, and outcome prediction of disease, however, only a limited number of biomarkers are available and none are suitable for early detection and screening of CRC. A PCR-based Epi proColon® blood plasma test for the detection of methylated SEPT9 has been approved by the USFDA for CRC screening in the USA, alongside a stool test for methylated DNA from CRC cells. However, these are reserved for patients who decline traditional screening methods. There remains an urgent need for the development of non-invasive molecular biomarkers that are highly specific and sensitive to CRC and that can be used routinely for early detection and screening. A molecular approach to the discovery of CRC biomarkers focuses on the analysis of the transcriptome of cancer cells to identify differentially expressed genes and proteins. A systematic search of the literature yielded over 100 differentially expressed CRC molecular markers, of which the vast majority are overexpressed in CRC. In terms of function, they largely belong to biological pathways involved in cell division, regulation of gene expression, or cell proliferation, to name a few. This review evaluates the current methods used for CRC screening, current availability of biomarkers, and new advances within the field of biomarker detection for screening and early diagnosis of CRC.

show abstract

Data mining combined with experiments to validate CEP55 as a prognostic biomarker in colorectal cancer

Cited by 9 publications

References 65 publications

Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma

Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma

An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)

Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection

Contact Info

Product

Resources

About